Comparative Pharmacology
Head-to-head clinical analysis: IMPLANON versus NEXTSTELLIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPLANON versus NEXTSTELLIS.
IMPLANON vs NEXTSTELLIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonogestrel, a progestin, binds to progesterone and androgen receptors, suppressing gonadotropin release (FSH, LH) and preventing ovulation. It also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial morphology.
Combination oral contraceptive: estrogen (estetrol) and progestin (drospirenone) suppress gonadotropin release, inhibiting ovulation; increase cervical mucus viscosity, impeding sperm penetration; alter endometrial lining, reducing implantation likelihood.
Insert 1 rod (68 mg etonogestrel) subdermally in the inner upper arm; replacement every 3 years.
One tablet orally once daily, each tablet containing drospirenone 3 mg and estetrol 14.2 mg, taken continuously without a break.
None Documented
None Documented
Terminal elimination half-life is approximately 25-30 hours; significant interindividual variability
Drospirenone: 30 hours; ethinyl estradiol: 12 hours. The long half-life allows once-daily dosing and stable serum concentrations.
Metabolites primarily excreted in urine (approximately 50%) and feces (30-35%)
Urine (60%) and feces (35%); drospirenone and metabolites, with enterohepatic recirculation.
Category C
Category C
Contraceptive
Contraceptive